Verified product status
Retatrutide Development and Approval Status
Lilly identifies retatrutide as an investigational triple agonist and states that it is not currently approved by FDA. Phase 3 topline announcements do not constitute marketing approval or a complete peer-reviewed evidence package.
Dated verification
What the reviewed sources establish
A regulatory proposal, advisory recommendation, clinical-development stage and marketing approval are kept as separate findings.
No FDA approval identified; sponsor states not approved
Lilly status page
Phase 3 program; selected 2026 topline results announced
Lilly status page and linked program records
Topline announcements remain distinct from full peer-reviewed reports and regulatory review
Editorial classification
Status timeline
Keep the date attached to the claim.
Later events do not retroactively change what an earlier source established. This timeline records the source context used for the current wording.
The 48-week randomized Phase 2 obesity trial was published.
Lilly reported selected Phase 3 TRIUMPH topline results while continuing to describe retatrutide as investigational.
Status page rechecked; no FDA approval is claimed.
Entity boundary
The name is not the approval.
This status describes Lilly’s investigational medicine and public development program. It does not establish identity, formulation, safety, efficacy or legal status for a catalog research material using the same name.
Research and regulatory information only. No clinical-use or dosing guidance.Primary and technical sources
Records used for this guide
Sources are linked directly so the wording, date and scope can be checked independently.
- 01Source record
What to know about retatrutide
Eli Lilly and Company. Medically reviewed; updated July 2026.
- 02Source record
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff AM, et al. N Engl J Med. 2023;389:514–526. PMID 37366315.
Knowledge center